
Abeona Therapeutics (ABEO) Stock Forecast & Price Target
Abeona Therapeutics (ABEO) Analyst Ratings
Bulls say
Abeona Therapeutics Inc. is projected to achieve approximately $32 million in top-line revenue for 2025, with significant expected growth to $130.4 million by 2026, suggesting a strong upward trajectory in financial performance. The company benefits from a favorable market access situation that is anticipated to improve, potentially enhancing revenue generation beyond current forecasts. Additionally, the promising pipeline of gene therapies and plasma-based products aimed at treating rare genetic diseases positions the firm for further incremental upside, supporting a positive outlook for its stock performance.
Bears say
Abeona Therapeutics Inc faces significant risks that contribute to a negative outlook, primarily related to the anticipated market performance and strategic execution of its leading product, pz-cel. Slow adoption rates in the U.S. market and challenges in realizing its potential value outside of the U.S. further exacerbate concerns, alongside the possibility of setbacks in the development of its earlier-stage pipeline programs. Additionally, the potential for long-term dilution poses a financial risk that may deter investor confidence, compounding the company's challenges in stabilizing its financial position.
This aggregate rating is based on analysts' research of Abeona Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Abeona Therapeutics (ABEO) Analyst Forecast & Price Prediction
Start investing in Abeona Therapeutics (ABEO)
Order type
Buy in
Order amount
Est. shares
0 shares